2023 annual financial data
BioCryst Pharmaceuticals 2023 Net margin
Direct answer
Net margin was -68.36%.
Operating income was -103,709,000 USD and net income was -226,539,000 USD.
Operating cash flow was -95,141,000 USD.
Get free BioCryst Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 331,412,000 USD
- Operating income
- -103,709,000 USD
- Net income
- -226,539,000 USD
- Operating cash flow
- -95,141,000 USD
Explore related company data
View all 2023 financial metricsView RevenueView Operating incomeView Net incomeView Operating cash flowView Revenue growthView Operating income growthView Net income growthView Operating cash flow growthView Operating marginView Operating cash flow marginView all BioCryst Pharmaceuticals financial years